Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Peking University First Hospital
Condition: Upper Urinary Tract Urothelial Carcinoma
NCT06210490
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.